オプションチェーンは、ENDRA Life Sciencesの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、ENDRA Life Sciencesの市場センチメントを評価します。.

ENDRA Life Sciences (NASDAQ:NDRA) 株価情報, オプションチェーン

ENDRA Life Sciences

ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI at the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.

ENDRA Life Sciences Inc

Gorman-Rupp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRC#NYSE">GRC</a>) reported quarterly earnings of $0.46 per share which beat the analyst consensus estimate of $0.44 by 4.55 percent. This is a 53.33 percent increase over earnings of $0.30 per share from the same period last year. The company reported quarterly sales of $163.95 million which missed the analyst consensus estimate of $165.02 million by 0.65 percent. This is a 2.94 percent increase over sales of $159.27 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

Gorman-Rupp Q1 EPS $0.46 Beats $0.44 Estimate, Sales $163.95M Miss $165.02M Estimate

Darling Ingredients CEO Says 'Despite the broader challenges faced by the biofuel industry during the first quarter of 2025, Darling Ingredients' core business performed well'

Dover (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOV#NYSE">DOV</a>) lowers FY2025 GAAP EPS guidance from $8.16-$8.36 to $8.04-$8.24 vs $8.27 analyst estimate..

Guidance

Dover Lowers FY2025 GAAP EPS Guidance from $8.16-$8.36 to $8.04-$8.24 vs $8.27 Est

Dover (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOV#NYSE">DOV</a>) lowers FY2025 Adj EPS guidance from $9.30-$9.50 to $9.20-$9.40 vs $9.25 analyst estimate. Affirms FY2025 sales outlook from $7.90 billion-$8.06 billion to $7.90 billion-$8.06 billion vs $8.01 billion estimate.

Dover Lowers FY2025 Adj EPS Guidance from $9.30-$9.50 to $9.20-$9.40 vs $9.25 Est; Affirms FY2025 Sales Guidance of $7.90B-$8.06B vs $8.01B Est

Darling Ingredients Sees FY25 Core Business Generating ~$950M-$1B EBITDA

Dover (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOV#NYSE">DOV</a>) reported quarterly earnings of $2.05 per share which beat the analyst consensus estimate of $1.98 by 3.54 percent. This is a 19.19 percent increase over earnings of $1.72 per share from the same period last year. The company reported quarterly sales of $1.87 billion which missed the analyst consensus estimate of $1.88 billion by 0.67 percent. This is a 0.96 percent decrease over sales of $1.88 billion the same period last year.

Dover Q1 Adj. EPS $2.05 Beats $1.98 Estimate, Sales $1.87B Miss $1.88B Estimate

First Citizens BancShares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NASDAQ">FCNCA</a>) reported quarterly earnings of $37.79 per share which missed the analyst consensus estimate of $37.91 by 0.32 percent. This is a 28.59 percent decrease over earnings of $52.92 per share from the same period last year. The company reported quarterly sales of $2.29 billion which beat the analyst consensus estimate of $2.26 billion by 1.58 percent. This is the same as the same period last year.

FCNCA

First Citizens BancShares Q1 Adj. EPS $37.79 Misses $37.91 Estimate, Sales $2.29B Beat $2.26B Estimate

Darling Ingredients Q1 EPS $(0.16) Misses $0.40 Estimate, Sales $1.38B Miss $1.45B Estimate

HC Wainwright &amp; Co. analyst Kevin Dede reiterates MARA Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) with a Buy and maintains $28 price target.

Price Target

Reiteration

Analyst Ratings

MARA

HC Wainwright & Co. Reiterates Buy on MARA Holdings, Maintains $28 Price Target

HC Wainwright &amp; Co. analyst Scott Buck reiterates FlexShopper (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FPAY#NASDAQ">FPAY</a>) with a Buy and maintains $2.5 price target.

FPAY

HC Wainwright & Co. Reiterates Buy on FlexShopper, Maintains $2.5 Price Target

KDP reaffirmed its fiscal 2025 guidance for constant currency net sales growth in a mid-single-digit range and Adjusted diluted EPS growth in a high-single-digit range.&nbsp;

Keurig Dr Pepper Reiterated FY25 Net Sales Growing In Mid-Single-Digit Range, Adj. EPS Growing In High-Single-Digit Range On Constant Currency Basis

Materialise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTLS#NASDAQ">MTLS</a>) lowers FY2025 sales outlook from $288.17 million-$304.18 million to $283.93 million-$299.71 million vs $278.67 million estimate.

MTLS

Materialise Lowers FY2025 Sales Guidance from $288.17M-$304.18M to $283.93M-$299.71M vs $278.67M Est

Donegal Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGICB#NASDAQ">DGICB</a>) reported quarterly earnings of $0.66 per share which beat the analyst consensus estimate of $0.36 by 83.33 percent. This is a 450 percent increase over earnings of $0.12 per share from the same period last year. The company reported quarterly sales of $245.17 million which missed the analyst consensus estimate of $249.36 million by 1.68 percent. This is a 1.67 percent increase over sales of $241.14 million the same period last year.

DGICB

Donegal Gr Q1 Adj. EPS $0.66 Beats $0.36 Estimate, Sales $245.17M Miss $249.36M Estimate

Donegal Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGICA#NASDAQ">DGICA</a>) reported quarterly earnings of $0.72 per share which beat the analyst consensus estimate of $0.36 by 100 percent. This is a 453.85 percent increase over earnings of $0.13 per share from the same period last year. The company reported quarterly sales of $245.17 million which missed the analyst consensus estimate of $249.36 million by 1.68 percent. This is a 1.67 percent increase over sales of $241.14 million the same period last year.

DGICA

Donegal Gr Q1 Adj. EPS $0.72 Beats $0.36 Estimate, Sales $245.17M Miss $249.36M Estimate

Commodities

Markets

General

CMS Energy Reaffirmed Its Long-term Adjusted EPS Growth Of 6%-8%

Textron (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TXT#NYSE">TXT</a>) affirms FY2025 Adj EPS guidance from $6.00-$6.20 to $6.00-$6.20 vs $6.08 analyst estimate..

Textron Affirms FY2025 Adj EPS Guidance of $6.00-$6.20 vs $6.08 Est

CMS Energy Affirms FY2025 Adj EPS Guidance of $3.54-$3.60 vs $3.59 Est

Centerpoint Provides Update That Current Interconnection Queue Is Up ~7Gws Since The End Of 2024, Strengthening Conviction In 50% Load Growth Forecast By 2031

Hasbro Announces Multi-Year Extension With Disney For Star Wars And Marvel Franchises Products

Keurig Dr Pepper Q1 Adj. EPS $0.42 Beats $0.38 Estimate, Sales $3.63B Beat $3.57B Estimate

Press Releases

ENDRA Life Sciences Announces Reverse Stock Split

ENDRA Life Sciences Reports Second Quarter 2024 Financial Results and Provides a Business Update

ENDRA Life Sciences Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirements

ENDRA Life Sciences Activates TAEUS System to Initiate Clinical Study at LMU University Hospital in Germany

ENDRA Life Sciences Further Strengthens TAEUS® Platform Intellectual Property with Issuance of 17th European Patent

Study Highlighting ENDRA Life Sciences' TAEUS Technology in Patients with High BMI to be Presented at AASLD's The Liver Meeting® 2024

ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update

ENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

ENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business Update

ENDRA Life Sciences Announces Enhanced Strategy to Enable the Early Detection and Management of Metabolic Diseases Facilitated by Emerging GLP-1 Therapies

Comments

ENDRA Life Sciences

ENDRA Life Sciences (NDRA) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル